Lumiracoxib

Lumiracoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was marketed by Novartis until 2007. It was used for the treatment of osteoarthritis, acute pain, and dysmenorrhea. Lumiracoxib was withdrawn from the market due to concerns about severe liver side effects.

History

Lumiracoxib was developed by Novartis and approved for use in the treatment of osteoarthritis in several countries in 2003. However, it was withdrawn from the market in 2007 due to concerns about severe liver side effects. The drug was never approved for use in the United States.

Pharmacology

Lumiracoxib is a COX-2 inhibitor, which means it works by blocking the enzyme cyclooxygenase-2 (COX-2). This enzyme is involved in the production of prostaglandins, which cause pain and inflammation in the body. By blocking COX-2, lumiracoxib reduces pain and inflammation.

Side effects

The most common side effects of lumiracoxib are nausea, dyspepsia, and diarrhea. However, the drug has also been associated with severe liver side effects, including hepatitis, jaundice, and liver failure. These side effects led to the withdrawal of lumiracoxib from the market in several countries.

Market withdrawal

In 2007, Novartis withdrew lumiracoxib from the market due to concerns about severe liver side effects. The decision was made after reports of serious liver problems in patients taking the drug, including several cases of liver failure that resulted in death or liver transplantation.

See also

• Nonsteroidal anti-inflammatory drug
• COX-2 inhibitor
• Novartis

‎